- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- October 2024
- 182 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- April 2025
- 196 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- March 2025
- 183 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- August 2022
- 120 Pages
Global
From €4096EUR$4,500USD£3,479GBP
Berinert is a brand of Immune Disorders Drugs used to treat hereditary angioedema (HAE). It is a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. Berinert is a C1-esterase inhibitor, which works by blocking the action of the enzyme that causes the swelling. It is administered as an intravenous infusion and is used to treat acute attacks of HAE. It is also used to prevent attacks in patients with a history of frequent attacks. Berinert is approved for use in adults and children over the age of two.
The Berinert market is composed of a variety of companies that produce and distribute the drug. These include CSL Behring, Shire, and ViroPharma. Other companies involved in the market include Grifols, Kedrion, and Octapharma. These companies are involved in the production, distribution, and marketing of Berinert. They also provide support services to patients and healthcare professionals. Show Less Read more